KCM
CMPX icon

Kingdon Capital Management’s Compass Therapeutics CMPX Stock Holding History

Kingdon Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.07M Buy
+1,400,000
New +$4.13M 0.31% 70

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Kingdon Capital Management's CMPX Position: Q2 2026 in Review

Kingdon Capital Management opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 1,400,000 shares worth $3.07M. The stake represents 0.31% of the portfolio and ranks #70 among its holdings.

215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Kingdon Capital Management held 1,400,000 shares of Compass Therapeutics worth $3.07M as of Q2 2026.
  • Compass Therapeutics was a new Kingdon Capital Management position in Q2 2026.
  • Compass Therapeutics made up 0.31% of Kingdon Capital Management's portfolio in Q2 2026, its #70 holding.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Kingdon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.